New combo aims to supercharge immune attack on tough melanoma
NCT ID NCT05089370
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-phase study tests whether adding an oral drug (DEC-C) to the immunotherapy nivolumab can help the immune system better attack mucosal melanoma, a rare and hard-to-treat skin cancer. The trial includes 8 adults with advanced disease that cannot be removed by surgery. The main goal is to check safety and find the best dose, while also seeing if the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.